南京地区34家医院2012－2014年呼吸系统吸入剂使用分析-中国药房

南京地区34家医院2012－2014年呼吸系统吸入剂使用分析

请在关注微信后，向客服人员索取文件

篇名：	南京地区34家医院2012－2014年呼吸系统吸入剂使用分析
TITLE：
摘要：	目的：为呼吸系统吸入剂的合理使用提供参考。方法：采用SPSS 13.0软件分析南京地区34家医院2012－2014年呼吸系统吸入剂的用药频度（DDDs）、销售金额、日均费用（DDC）和医保与自费金额等数据。结果：南京地区34家医院2012－2014年呼吸系统吸入剂共涉及4种类型、5种剂型、12种通用名和38种商品名（规格）。呼吸系统吸入剂总DDDs和总销售金额分别从2012年的10 827.46×103和7 100.65万元增至2014年的14 627.25×103和9 913.71万元，但增长趋势均无统计学意义（P＞0.05）。4种类型呼吸系统吸入剂DDDs排名依次为抗胆碱能药物、复合制剂、糖皮质激素和β2受体激动药，各类型DDDs均逐年增加，但仅抗胆碱能药物DDDs增加趋势有统计学意义（P＜0.01）；销售金额排名依次为糖皮质激素、复合制剂、胆碱能药物和β2受体激动药，各类型销售金额均逐年增加，但增加趋势均无统计学意义（P＞0.05）。5种剂型呼吸系统吸入剂DDDs排名依次为气雾剂、粉雾剂、雾化溶液、鼻喷剂和肺部输药器，气雾剂和粉雾剂DDDs均逐年增加，趋势有统计学意义（P＜0.05）；2012－2013年销售金额居首位的均为粉雾剂，2014年为雾化溶液，而3年总销售金额位居首位的仍为粉雾剂。12种通用名吸入剂DDDs排名前4位的药品是溴化异丙基阿托品、沙美特罗替卡松、沙丁胺醇和布地奈德，其3年总DDDs构成比分别为40.16％、16.71％、13.51％和13.39％，构成比合计＞80％；销售金额排名前3位的药品是布地奈德、沙美特罗替卡松和布地奈德福莫特罗，其3年总销售金额构成比分别占39.59％、20.81％和12.50％，且构成比合计＞70％。沙丁胺醇DDC最低。38种商品名（规格）吸入剂中，医保品种和医保金额分别占92.11％和95.02％。普米克令舒雾化混悬液医保金额居首位，信必可都保（160 μg）自费金额居首位，都属乙类医保药品。结论：南京34家医院2012－2014年呼吸系统吸入剂总体使用基本合理。
ABSTRACT：	OBJECTIVE： To provide reference for rational use of respiratory inhalants. METHODS： The utilization of respiratory inhalants in 34 hospitals from Nanjing area during 2012-2014 was analyzed by SPSS13.0 software in respects of DDDs， consumption sum， DDC， health insurance and self-paying cost and so on. RESULTS： Respiratory inhalants involved 4 kinds of drugs， 5 kinds of dosage forms， 12 kinds of general name and 38 kinds of trade name （specification） in 34 hospitals from Nanjing area during 2012-2014. The total DDDs and total consumption sum of respiratory inhalants increased from 10 827.46×103 and 71，006，500 yuan in 2012 and 14 627.25×103 and 99，137，100 yuan in 2014， there was no statistical significance （P＞0.05）. 4 categories of respiratory inhalants in the list of DDDs were anticholinergic agents， compound preparations， glucocorticoid and β2 receptor agonists； DDDs of each type increased year by year， but only that of anticholinergic agents had statistical significance （P＜0.01）. Consumption sum were glucocorticoid， compound preparations， anticholinergic agents and β2 receptor agonists； consumption sum of each type increased year by year， but there was no statistical significance （P＞0.05）. 5 kinds of inhalants in the list of DDDs were aerosol preparation， power aerosols， atomizing solution， nasal spray and clickhaler. DDDs of aerosol preparation and power aerosols increased year by year， with statistical significance （P＜0.05）. Top one in the list of consumption sum was power aerosols during 2012-2013 and atomizing solution in 2014； power aerosols took up the first place in the list of total consumption in 3 years. Among 12 kinds of general name inhalants， top 4 inhalants in the list of DDDs were ipratropium bromide， salmeterol and fluticasone， albuterol and budesonide， and the constituent ratio of their total DDDs in 3 years were 40.16％， 16.71％， 13.51％ and 13.39％， respectively； the sum of constituent ratio of total DDDs in 3 years was more than 80％. Top 3 inhalants in the list of consumption sum were budesonide， salmeterol and fluticasone， budesonide and formoterol， and the sum of constituent ratio of their total consumption sum in 3 years were 39.59％， 20.81％ and 12.50％， respectively； the sum of constituent ratio was more than 70％. DDC of salbutamol was the lowest. Among 38 kinds of trade name （specification） inhalants， the type and cost of health insurance accounted for 92.11％ and 95.02％. Pulmicort atomization suspension and Symbicort Turbuhaler （160 μg） took up the first place in the list of health insurance cost and self-paying cost respectively， and they were B directory of health insurance. CONCLUSIONS： The utilization of respiratory inhalants was basically reasonable in 34 hospitals from Nanjing during 2012-2014.
期刊：	2016年第27卷第20期
作者：	许亚洲，俞颖，曹加，刘晓亮
AUTHORS：	XU Yazhou，YU Ying，CAO Jia，LIU Xiaoliang
关键字：	呼吸系统吸入剂；用药频度；销售金额；日均费用；医保；自费
KEYWORDS：	Respiratory inhalants； DDDs； Consumption sum； Average daily cost； Health insurance； Self-paying cost
阅读数：	291 次
本月下载数：	2 次

* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！